This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Similar Posts
PAIN FLEX may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use PAIN FLEX, a product promoted and sold for joint pain on various websites, including Amazon.com and possibly in some retail stores.FDA Roundup: May 31, 2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression
FDA is requiring new warnings about the risk of serious breathing difficulties that can lead to death in patients who use gabapentanoids with opioid pain medicines or other drugs that depress the central nervous system.Drug Trials Snapshots: VIZZ
Drug Trials Snapshots: VIZZEyeTech One, LLC – 712438 – 07/09/2025
Unapproved New Drugs/MisbrandedPatient-Focused Drug Development
The OCE PFDD program fosters collaboration between FDA centers and external stakeholders involved in patient outcomes research in cancer populations.